Kyverna Therapeutics to Present Phase 2 Trial Results for KYV-101

Kyverna Therapeutics, Inc., a biopharmaceutical company based in Emeryville, California, announced that it will present topline results from its registrational Phase 2 clinical trial, known as KYSA-8, evaluating the efficacy of KYV-101 in treating Stiff Person Syndrome (SPS). The live webcast and conference call is scheduled for December 15, 2025, at 8:00 am ET.

This trial is pivotal for Kyverna as it explores a potential therapy for SPS, a rare neurological disorder characterized by stiffness and spasms in the muscles. The results from KYSA-8 could provide important insights into the effectiveness of KYV-101, potentially influencing treatment options for patients suffering from this debilitating condition.

During the conference, executives and clinical team members will discuss the implications of the findings and outline the next steps for the drug’s development. This presentation is expected to draw significant attention from investors and healthcare professionals alike, given the ongoing interest in innovative treatments for autoimmune diseases.

Kyverna Therapeutics is dedicated to advancing cell therapies aimed at improving the quality of life for individuals with autoimmune disorders. The company has made strides in its research and development efforts, seeking to address unmet medical needs in this area.

As the biopharmaceutical landscape continues to evolve, the KYSA-8 trial results could play a crucial role in shaping future research initiatives. Stakeholders are encouraged to tune in to the webcast for the latest updates on this important clinical trial and its outcomes.

For those interested in participating, details on accessing the conference call will be available on the company’s official website.